Trillium Therapeutics Announces Dosing of First Patient in Phase Ib/II Study of TTI-622 in Combination with Azacitidine in TP53-Mutated Acute Myeloid Leukemia

Trillium Therapeutics, Inc. announced that it has dosed the first TP53-mutated acute myeloid leukemia patient with TTI-622, an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine.